Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ryan R. Willard
Observed names:
R R. Willard,
R Willard,
RR Willard,
Ryan R Willard,
Ryan Willard
Observed institutions:
Agricultural Research Service,
United States Department of Agriculture,
Yale University,
Beltsville Agricultural Research Center,
Arvinas (United States)
ORCID:
0009-0009-0048-6999
Observed ORCID:
0009-0009-0048-6999
OpenAlex ID:
A5000833342
Catalytic in vivo protein knockdown by small-molecule PROTACs
2015
·
Daniel P Bondeson
, Alina Mares
, et al.
·
Nature Chemical Biology
·
1,372
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
2018
·
Jemilat Salami
, Shanique Alabi
, et al.
·
Communications Biology
·
354
PDF
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
2019
·
Taavi Neklesa
, Lawrence B Snyder
, et al.
·
Journal of Clinical Oncology
·
222
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
2024
·
Sheryl M. Gough
, John J. Flanagan
, et al.
·
Clinical Cancer Research
·
219
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
2019
·
JJ Flanagan
, Y Qian
, et al.
·
Cancer Research
·
139
Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer
2021
·
Lawrence B. Snyder
, John J. Flanagan
, et al.
·
Cancer Research
·
128
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2024
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
·
Molecular Cancer Therapeutics
·
104
PDF
Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer
2021
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
·
Cancer Research
·
78
Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
2018
·
Taavi Neklesa
, Lawrence B. Snyder
, et al.
·
Cancer Research
·
65
An oral androgen receptor PROTAC degrader for prostate cancer.
2017
·
Taavi K Neklesa
, Lawrence B Snyder
, et al.
·
Journal of Clinical Oncology
·
29
Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
2023
·
Larry Snyder
, S H. Lee
, et al.
·
Cancer Research
·
27
An oral androgen receptor PROTAC degrader for prostate cancer.
2018
·
Taavi Neklesa
, Lawrence B Snyder
, et al.
·
Journal of Clinical Oncology
·
15
ARV-330: Androgen receptor PROTAC degrader for prostate cancer.
2016
·
Taavi K Neklesa
, Meizhong Jin
, et al.
·
Journal of Clinical Oncology
·
13
Characterization of Two Subpopulations of the PICM-19 Porcine Liver Stem Cell Line for use in Cell-Based Extracorporeal Liver Assistance Devices
2010
·
Neil C. Talbot
, Thomas J. Caperna
, et al.
·
The International Journal of Artificial Organs
·
10
Cytochrome P450 expression profile of the PICM-19H pig liver cell line: potential application to rapid liver toxicity assays
2009
·
Ryan R. Willard
, Nancy W. Shappell
, et al.
·
In Vitro Cellular & Developmental Biology - Animal
·
10
Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer
2018
·
JJ Flanagan
, Y Qian
, et al.
·
Cancer Research
·
3
Data from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2025
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
·
2
Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer
2017
·
Taavi K. Neklesa
, Lawrence B. Snyder
, et al.
·
Cancer Research
·
2
Abstract LB-097: Targeted degradation of the androgen receptor in prostate cancer
2015
·
Meizhong Jin
, James D. Winkler
, et al.
·
Cancer Research
·
2
Supplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2025
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
·
1
Data from Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
2024
·
Sheryl M. Gough
, John J. Flanagan
, et al.
·
1
Abstract PR08: ARV-330: An androgen receptor PROTAC degrader for prostate cancer
2015
·
James D. Winkler
, Meizhong Jin
, et al.
·
Molecular Cancer Therapeutics
·
1
Supplementary Figure S4 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2026
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
Supplementary Figure S2 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2026
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
Supplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2026
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
Show more works
View as search
Works count:
39
Citation count:
2,797
H-index:
13
I10-index:
15
Year
Topic
Type
